SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Seltzer SE, Holman BL. Imaging hepatic metastases from colorectal carcinoma: identification of candidates for partial hepatectomy. AJR 1989; 152:917923.
  • 2
    Heiken JP, Weyman PJ, Lee JK et al. Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989; 171:4751.
  • 3
    Heiken JP, Brink JA, McClennan BL et al. Dynamic contrast-enhanced CT of the liver: comparison of contrast medium injection rates and uniphasic and biphasic injection protocols. Radiology 1993; 187:327331.
  • 4
    Runge VM, Rijcken THP, Davidoff A, Wells JW, Stark DD. Contrast-enhanced MR imaging of the liver. J Magn Reson Imaging 1994; 4:281289.
  • 5
    Elizondo G, Fretz CJ, Stark DD et al. Preclinical evaluation of Mn-DPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 1991; 178:7378.
  • 6
    Lim KO, Stark DD, Leese PT et al. Hepatobiliary MR imaging: first human experience with MnDPDP. Radiology 1991; 178:7982.
  • 7
    Rofsky NM, Weinreb JC, Bernardino ME et al. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. Radiology 1993; 188:5359.
  • 8
    Bernardino ME, Young SW, Lee JK, Weinreb J. Contrast-enhanced magnetic resonance imaging of the liver with Mn-DPDP for known or suspected focal hepatic disease. Invest Radiol 1991; 26:S148S149.
  • 9
    Bernardino ME, Young SW, Lee JK, Weinreb JC. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 1992; 183:5358.
  • 10
    Birnbaum BA, Weinreb JC, Fernandez MP et al. Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions: initial findings. Clin Imaging 1994; 18:2127.
  • 11
    Unpublished data.
  • 12
    Hamm B, Vogl TJ, Branding G et al. Focal liver lesions: MR imaging with MnDPDP. Initial clinical results in 40 patients. Radiology 1992; 182:167174.
  • 13
    Vogl TJ, Hamm B, Schnell B et al. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images. J Magn Reson Imaging 1993; 3:5158.
  • 14
    Aicher KP, Laniado M, Kopp AF et al. Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients. J Magn Reson Imaging 1993; 3:731737.
  • 15
    Rummeny E, Ehrenheim C, Gehl HB et al. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients. Invest Radiol 1991; 26(suppl 1):S142S145.
  • 16
    Kopp AF, Laniado M, Aicher KP, Gronewaller EF, Claussen CD. Manganese DPDP as a contrast medium for MRI of focal liver lesions: patient acceptability and image quality in 20 patients. Fortschr Roentgenstr Neuen Bildgeb Verfahr 1992; 157:539547.
  • 17
    Vogl TJ, Hamm B, Schnell B, Eibl-Eibesfeldt B, Steiner S, Lissner J. The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver. Fortschr Roentgenstr Neuen Bildgeb Verfahr 1991; 155:568574.
  • 18
    Steudel A, Layer G, Kraheck H, Hartlapp J, Reiser M. Malignant liver tumors in hepatobiliary MR imaging with Mn-DPDP. Fortschr Roentgenstr Neuen Bildgeb Verfahr 1992; 156:460464.
  • 19
    Laniado M, Ehrenheim C, Gehl H et al. Mn-DPDP: safety profile after phase II clinical trials in 140 patients. Radiology 1991;179:121.
  • 20
    Rummeny E, Ehrenheim C, Gehl HB et al. Value of Mn-DPDP-enhanced MR imaging of liver tumors in 141 patients: results of phase II trials in Germany. Radiology 1991; 178:7378.
  • 21
    Harmon B, Fenstermacher M, Pelsang RE et al. The efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials. Efficacy of delayed imaging. (submitted).
  • 22
    Federle MP, Chezmar JL, Rubin DL et al. The safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials. Safety. (accepted).
  • 23
    Ahlstrom H, Gehl HB. Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging. Acta Radiol 1997; 38:660664.
  • 24
    Blume J, Palmie S, Aue B. Pancreatic contrast enhancement with Mn-bis pyridoxal ethylene diamine diacetic acid and the influence of a hormonal stimulation of the pancreas in pigs. Acad Radiol 1994; 1:253260.
  • 25
    Coley BD, Mattrey RF, Baker KG, Peterson T, Burgan AR. MR imaging assessment of experimental hepatic dysfunction with Mn-DPDP. J Magn Reson Imaging 1995; 5:1116.
  • 26
    Khangure MS, Hua J. Comparative assessment of gadoxetate disodium, manganese dipyridoxal diphosphate, and superparamagnetic iron oxide for enhancement of the liver in dogs. Acad Radiol 1996; 3(suppl 2):S458S460.
  • 27
    Kreft BP, Tanimoto A, Baba Y et al. Enhanced tumor detection in the presence of fatty liver disease: cell-specific contrast agents. J Magn Reson Imaging 1994; 4:337342.
  • 28
    Leander P, Golman K, Klaveness J et al. MRI contrast media for the liver. Efficacy in conditions of acute biliary obstruction. Invest Radiol 1990; 25:11301134.
  • 29
    Leander P, Mansson S, Ege T, Besjakov J. CT and MR imaging of the liver using liver-specific contrast media. A comparative study in a tumour model. Acta Radiol 1996; 37:242249.
  • 30
    Marchal G, Ni Y, Zhang X et al. Mn-DPDP enhanced MRI in experimental bile duct obstruction. J Comput Assist Tomogr 1993; 17:290296.
  • 31
    Marchal G, Zhang X, Ni Y et al. Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: a correlation study of MR imaging, microangiography, and histology. Magn Reson Imaging 1993; 11:665674.
  • 32
    Nelson RC, Chezmar JL, Newberry LB et al. Manganese dipyridoxal diphosphate. Effect of dose, time, and pulse sequence on hepatic enhancement in rats. Invest Radiol 1991; 26:569573.
  • 33
    Nelson RC, Chezmar JL, Thompson GH et al. Magnetic resonance imaging after arterial portography with manganese dipyridoxal diphosphate. Invest Radiol 1993; 28:335340.
  • 34
    Ni Y, Marchal G, Zhang X et al. The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularization. Invest Radiol 1993; 28:520528.
  • 35
    Ni Y, Petre C, Bosmans H et al. Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnC12. Acta Radiol 1997; 38:700707.
  • 36
    Ni Y, Petre C, Lukito G et al. Effect of manganese dipyridoxal diphosphate on liver magnetic resonance imaging and serum bilirubin in rats with removable biliary obstruction. Acad Radiol 1995; 2:300305.
  • 37
    Pomeroy OH, Wendland M, Wagner S et al. Magnetic resonance imaging of acute myocardial ischemia using a manganese chelate, Mn-DPDP. Invest Radiol 1989; 24:531536.
  • 38
    Rubin DL, Muller HH, Young SW. Formulation of radiographically detectable gastrointestinal contrast agents for magnetic resonance imaging: effects of a barium sulfate additive on MR contrast agent effectiveness. Magn Reson Med 1992; 23:154165.
  • 39
    Sidhu MK, Muller HH, Aggeler J, Jones AL, Young SW. Manganese dipyridoxal diphosphate-enhanced magnetic resonance imaging in the evaluation of hepatocyte function. Invest Radiol 1993; 28:903910.
  • 40
    Southon TE, Grant D, Bjornerud A et al. NMR relaxation studies with MnDPDP. Acta Radiol 1997; 38:708716.
  • 41
    Tanimoto A, Kreft BP, Baba Y et al. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis. J Magn Reson Imaging 1993; 3:786793.
  • 42
    Thorstensen O, Isberg B, Jorulf H et al. MnDPDP enhancement in rabbit liver after intravenous bolus injection and slow infusion. Acta Radiol 1997; 38:717723.
  • 43
    Young SW, Bradley B, Muller HH, Rubin DL. Detection of hepatic malignancies using MnDPDP (manganese dipyridoxal diphosphate) hepatobiliary MRI contrast agent. Magn Reson Imaging 1990; 8:267276.
  • 44
    Young SW, Simpson BB, Ratner AV, Matkin C, Carter EA. MRI measurement of hepatocyte toxicity using the new MRI contrast agent manganese dipyridoxal diphosphate, a manganese/pyridoxal 5-phosphate chelate. Magn Reson Med 1989; 10:113.
  • 45
    Toft KG, Hustvedt SO, Grant D et al. Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol 1997; 38:677689.
  • 46
    Wang C, Gordon PB, Hustvedt SO et al. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol 1997; 38:665676.
  • 47
    Dinoto DR, Kennedy CD, Johnson JA et al. Pharmacokinetics and biotransformation of the MRI liver contrast agent mangafodipir trisodium injection in normal human male volunteers. In: Proceedings of the 4th International ISSX Meeting, Seattle, 1995. Vol 8, p 323.
  • 48
    Rofsky NM, Weinreb JC. Manganese (II) N,N`-dipyridoxalethylenediamine-N,N`-diacetate 5,5`-bis(phosphate): clinical experience with a new contrast agent. Magn Reson 1992; 8:156168.
  • 49
    Rofsky NM, Earls JP. Mangafodipir trisodium injection (Mn-DPDP): a contrast agent for abdominal MR imaging. Magn Reson Imaging Clin N Am 1996; 4:7385.
  • 50
    Aicher KP, Kopp AF, Gronewaller E, Rummeny E, Laniado M. Manganese-DPDP-enhanced MRI of liver metastases. In: Proceedings of The American Roentgen Ray Society Ninety-first Annual Meeting, 1991, Boston, 1991. p 201.
  • 51
    Gehl HB, Gunther RW, Klever P, Hauptmann S. Manganese dipyridoxal diphosphate as a new contrast medium in the MRT of benign and malignant pancreatic tumors: initial clinical findings. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1993; 159:240244.
  • 52
    Gehl HB, Urhahn R, Bohndorf K et al. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience. Radiology 1993; 186:795798.
  • 53
    Gehl HB, Urhahn R, Klever P, Lodemann KP, Guenther RW. Mn-DPDP in detection of pancreatic lesions with MR imaging. Results of a phase II trial. Radiology 1992;185:118.
  • 54
    Gehl HB, Vorwerk D, Klose KC, Raber H, Gunther RW. Mn-DPDP-enhanced imaging of the kidneys. First results of signal intensity changes and corticomedullary differentiation after low-dosage infusion. Radiology 1990;177:292.
  • 55
    Gehl HB, Vorwerk D, Klose KC, Gunther RW. Pancreatic enhancement after low-dose infusion of Mn-DPDP. Radiology 1991; 180:337339.
  • 56
    Laniado M, Kopp AF. Gegenwartiger Stand der klinischen Entwicklung von MR-Kontrastmitteln. Fortschr Rontgenstr Neuen Bildgeb Verfahr 1997; 167:541550.
  • 57
    Rummeny E, Lodemann KP. Mn-DPDP in the detection of hepatic tumors: results of clinical multicenter trials including 140 patients. Radiology 1991;181:121.
  • 58
    Wang C, Ahlstrom H, Ekholm S et al. Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicenter study. Acta Radiol 1997; 38:643649.
  • 59
    Rummeny EJ, Toffes CG, Kurdziel JC et al. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies. Acta Radiol 1997; 38:638642.
  • 60
    Torres CG, Lundby B, Sterud AT et al. MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol 1997; 38:631637.
  • 61
    Marti-Bonmati L, Lonjedo E, Mathiew D et al. Tumoural portal vein thrombosis. Enhancement with MnDPDP. Acta Radiol 1997; 38:655659.
  • 62
    Kane PA, Ayton V, Walters HL et al. MnDPD-enhanced MR imaging of the liver. Correlation with surgical findings. Acta Radiol 1997; 38:650654.
  • 63
    Padovani B, Lecesne R, Raffaelli C et al. Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 μmol/kg body weight in detecting focal liver tumors: results of a phase III trial using an infusion technique. Eur J Radiol 1996; 23:205211.
  • 64
    Halavaara JT, Lamminen AE. MnDPDP as a negative hepatic contrast agent: evaluation of STIR imaging compared with T1-weighted SE and GE techniques. J Comput Assist Tomogr 1997; 21:9499.
  • 65
    Materne R, Van Beers BE, Gigot JF et al. Inflammatory pseudotumor of the liver: MRI with mangafodipir trisodium. J Comput Assist Tomogr 1998; 22:8284.
  • 66
    Agresti A. Testing marginal homogeneity or ordinal categorical variables. Biometrics 1983; 39:505510.
  • 67
    Murakami T, Baron RL, Peterson MS et al. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996; 200:6977.
  • 68
    Murakami T, Baron RL, Federle MP et al. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996; 198:567572.